Status:

ACTIVE_NOT_RECRUITING

Fetal Treatment of Galenic Malformations

Lead Sponsor:

Darren Orbach

Conditions:

Vein of Galen Malformations

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

This is a prospective, single-arm non-randomized interventional study of fetuses to assess the safety and efficacy of fetal embolization of Vein of Galen Malformation (VOGM). Subjects will receive a o...

Detailed Description

The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL ...

Eligibility Criteria

Inclusion

  • Pregnant woman carrying a fetus harboring a vein of Galen malformation in whom the straight sinus or falcine sinus draining the prosencephalic varix measures 7 mm or more on fetal MRI (medio-lateral diameter measured at the narrowest point of the sinus along the rostral-caudal axis, assessed on a T2-weighted coronal slice).
  • Fetal gestational age between 23 weeks and term as determined by clinical information and evaluation of first ultrasound.
  • Anatomic diagnosis of fetal vein of Galen malformation.
  • Well preserved brain parenchyma.
  • Maternal age of 18 years and older.
  • Eligible for continuous lumbar epidural anesthesia.
  • Able to travel to study site for study evaluation, procedures and visits.

Exclusion

  • Extensive fetal brain parenchymal injury/gliosis, \>10% of supratentorial brain volume (i.e., SFP presentation). This is a degree of fetal brain injury beyond which the risk of significant neurological morbidity is high, based on studies of prenatal ischemic stroke.
  • Irreversible fetal non-brain organ injury (e.g. hydrops fetalis as a manifestation of heart failure, a finding which portends fatal outcome in fetuses with vein of Galen malformation), i.e., SFP presentation.
  • Fetus with VOGM in whom the straight sinus or falcine sinus draining the prosencephalic varix measures less than 7 mm on fetal MRI (T2-weighted coronal slice, medio-lateral diameter measured at the narrowest point of the sinus along the anterior-posterior axis), fitting fetal MRI criteria for likely evolution into the IT cohort.
  • Severe maternal obesity pre-pregnancy as defined by body mass index (BMI) of 40 or greater.
  • Fetuses with major congenital anomalies.
  • Evidence of preterm labor, rupture of membranes or abruption.
  • Maternal coagulopathy: INR \> 1.2; PT/PTT above normal ranges for the lab; platelets \<100.
  • Medical disease requiring current anticoagulation including maternal deep vein thrombosis.
  • Prior maternal medical history that would preclude epidural anesthesia.
  • Multi-fetal pregnancy.
  • Placenta previa or accreta.
  • Participation in another fetal study that influences maternal and fetal morbidity and mortality.
  • Known maternal hypersensitivity to 316LM stainless steel.
  • Supine hypotensive syndrome.

Key Trial Info

Start Date :

September 30 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2026

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT04434729

Start Date

September 30 2022

End Date

August 1 2026

Last Update

January 6 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boston Children's Hospital

Boston, Massachusetts, United States, 02115